Roche’s Hemlibra has been approved in an expanded use in haemophilia A in the US, as the Swiss firm seeks to build a new blockbuster franchise in rare diseases.
The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is
Roche has revealed new trial data that make the case for use of its haemophilia A drug Hemlibra in an expanded patient group, ahead of a decision by the FDA in the autumn.
US pharma giant Pfizer and partner Spark Therapeutics has begun a phase 3 trial of a gene therapy for patients with haemophilia B, which could see an end to patients needing constant inject